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Itziar Martı´nez-Gonza´lez,1,* Rafael Moreno,2,* Jordi Petriz,3 Eduard Grataco´s,4 and Josep M. Aran1
Due to their favorable intrinsic features, including engraftment, differentiation, and immunomodulatory potential,
adult mesenchymal stem cells (MSCs) have been proposed for therapeutic in utero intervention. Further improve-
ment of such attributes for particular diseases might merely be achieved by ex vivo MSC genetic engineering
previous to transplantation. Here, we evaluated for the first time the feasibility, biodistribution, long-term engraft-
ment, and transgenic enhanced green fluorescent protein (EGFP) expression of genetically engineered human adi-
pose tissue-derived MSCs (EGFP+ -ASCs) after intra-amniotic xenotransplantation at E17 of gestation into our
validated pregnant rabbit model. Overall, the procedure was safe (86.4% survival rate; absence of anatomical
defects). Stable, low-level engraftment of EGFP+ -ASCs was confirmed by assessing the presence of the pWT-EGFP
lentiviral provirus in the young transplanted rabbit tissues. Accordingly, similar frequencies of provirus-positive
animals were found at both 8 weeks (60%) and 16 weeks (66.7%) after in utero intervention. The presence of EGFP+ -
ASCs was more frequent in respiratory epithelia (lung and trachea), according to the route of administration.
However, we were unable to detect EGFP expression, neither by real-time polymerase chain reaction nor by
immunohistochemistry, in the provirus-positive tissues, suggesting EGFP transgene silencing mediated by epigenetic
events. Moreover, we noticed lack of both host cellular immune responses against xenogeneic ASCs and humoral
immune responses against transgenic EGFP. Therefore, the fetal microchimerism achieved by the EGFP+ -ASCs in
the young rabbit hosts indicates induction of donor-specific tolerance after fetal rabbit xenotransplantation, which
should boost postnatal transplantation for the early treatment/prevention of many devastating congenital disorders.
Introduction
To date, only a few genetic disorders have been treatedin utero with some success. However, the proof of prin-
ciple for the early treatment of inherited diseases by prenatal
gene therapy has been extensively demonstrated in several
animalmodels [1]. Despite the great potential of prenatal gene
therapy, safety problems particularly associated with the use
of integrative vectors (risk of insertional mutagenesis, germ-
line transmission, or abnormal organogenesis [2–4]) high-
lighted that new approaches are necessary to circumvent and/
or minimize these adverse events before fetal gene therapy
could be accepted for clinical application. An encouraging
alternative to improve the efficacy of prenatal therapy is the
use of stem cells as therapeutic agents, either unmodified or
genetically engineered using viral or nonviral vectors.
In utero stem cell administration would share some of the
advantages of prenatal gene therapy: (i) the early fetus
presents a relative immature immune system, providing a
favorable environment for allogeneic or xenogeneic grafts;
(ii) the small size of the fetus facilitates increased donor-to-
host-cell ratio; and (iii) prenatal administration may prevent
many genetic disorders before a definitive organ damage has
occurred. In addition, fetal cell therapy has also some ad-
vantages per se such as the possibility that stem cells could
engraft at several stem cell niches, increasing their expansion;
thanks to the high rate of proliferative and migratory events
that occur during ontogeny [5]. Finally, whether a combi-
nation of cell and gene therapy with integrative vectors
would be necessary, the risk associated with insertional
mutagenesis might be minimized by performing ex vivo
clonal analysis before cell expansion and administration,
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selecting those stem cell clones in which the vector has been
inserted into favorable loci.
At present, prenatal hematopoietic stem cell (HSC) trans-
plantation has been the most developed application for fetal
stem cell therapy. Numerous groups have demonstrated
diverse degrees of engraftment after in utero HSC adminis-
tration in animal models. However, significant engraftment
has been only documented when cell transplantation was
made on stem cell-deficient recipients, where there is a
competitive advantage for donor HSCs [6]. Interestingly,
studies carried out by Zanjani and col. demonstrated that
cotransplantation of mesenchymal stem cells (MSCs) en-
hanced the engraftment of HSCs after fetal administration
[7], pointing out the adjuvant potential of MSCs.
MSCs are multipotent nonhematopoietic cells, easily iso-
lated and expanded ex vivo from a great variety of sources
and species, with the capability to differentiate into a variety
of cell types of mesenchymal origin such as adipocytes,
chondrocytes, osteocytes, and tenocytes, and into other cell
types such as myocytes, astrocytes, and neurons [8]. Fur-
thermore, MSCs present low inherent immunogenicity [9].
The main functions described for MSCs include hematopoi-
esis regulation, apoptosis prevention, cellular repair, and the
control of immune–inflammatory reactions [10]. All these
attributes make MSCs particularly appealing in tissue repair
and regenerative medicine. Therefore, special efforts are be-
ing focused in the development of preclinical in utero MSC
transplantation studies. In fact, several reports have con-
firmed that fetal administration of MSCs resulted in correct
engraftment and differentiation of transplanted cells [11–13].
To advance toward clinical application, we have focused
our efforts elucidating the capacity of MSCs as cell vehicles
in prenatal studies, after ex vivo transduction with integra-
tive vectors. We have recently evaluated the overall safety,
biodistribution, engraftment capacity, and transgene ex-
pression of enhanced green fluorescent protein (EGFP)-
expressing rabbit fetal liver MSCs (EGFP + -fl-MSCs) after
allogeneic fetal transplantation into the pregnant rabbit
model [14]. We highlighted the safety of fl-MSCs for fetal
transplantation in the pregnant rabbit model, the efficiency,
and persistence of fl-MSC engraftment and transgene ex-
pression in fetal organs, and the absence of immune reactions
against both allogeneic fl-MSCs and transgenic EGFP after
fetal transplantation.
Based on our results and once established the pregnant
rabbit as a reliable middle-size animal model to evaluate
prenatal stem cell approaches, we decided to evaluate the
capability of a widely characterized MSC type with higher
ethical and clinical relevance: adult human adipose tissue-
derived MSCs (ASCs), transduced with an integrative vector
for in utero combined gene and cell therapy through intra-
amniotic administration. This approach might become
particularly appropriate for the treatment of congenital
respiratory diseases.
Materials and Methods
Isolation and characterization of human ASCs
According to the Institutional Ethics Committee guide-
lines, ASCs were isolated from discarded human adipose
tissue obtained from a healthy adult female undergoing
elective lipoaspiration, as recently described [15]. Briefly, the
raw lipoaspirate was washed extensively with an equal
volume of phosphate-buffered saline (PBS) (Invitrogen) to
remove blood cells, local anesthetic, and cellular debris. The
washed tissue was then resuspended in PBS containing
0.075% type II collagenase (Invitrogen) and incubated at
37C for 1 h. The enzymatic activity was neutralized by
adding an equal volume of the Dulbecco’s modified Eagle’s
medium (DMEM; Invitrogen) containing 10% fetal bovine
serum (FBS). The resulting suspension was filtered through a
70-mm nylon filter and centrifuged at 1200 g for 10min. The
pellet was resuspended in an a-MEM (Invitrogen) containing
10% FBS, 1% penicillin/streptomycin, 1% l-glutamine, and
2.5 mg/mL amphotericin (all from Invitrogen), and seeded
overnight in culture flasks (Corning, Inc.) at 37C in a 5%
CO2 atmosphere.
Next day, the cell monolayer was washed once more with
PBS to remove nonadherent cells and cellular debris and
replaced with a fresh medium. Finally, the ASCs were am-
plified for 10–12 days (passage 0) until 75%–90% confluent,
substituting the culture medium every 3–4 days, and were
passaged periodically by detachment [0.25% trypsin-1mM
EDTA in PBS (Invitrogen)] after achieving a subconfluent
monolayer.
The isolated ASCs were further characterized by cell sur-
face marker expression and differentiation capability [15].
Human ASC transduction and sorting
The replication-defective self-inactivating HIV-1-derived
lentiviral vector pWPT-EGFP [16], expressing the EGFP,
was produced and employed to generate the EGFP + -ASC
population.
ASCs (passage 1) were transduced by spinoculation.
About 5 · 105 ASCs and 5· 104 viral vector particles (MOI =
0.1) were cocultured on a 6-well cell culture plate (Corning
Inc.) with 2mL/well a-MEM complete medium plus 8mg/
mL of polybrene (Sigma), and centrifuged at 1000 g for
90min at 32C. Next day, the cell culture supernatant was
replaced by a fresh medium, and the cells were cultured for
another 24 h. The resulting EGFP+ fluorescent ASCs (Fig.
1A) were excited at 488 nm, sorted through a 530/40-band
pass filter, recovered as bulk populations of 1.5 · 105 cells
using a MoFlo jet-in-air high-speed sorter (Beckman Coul-
ter), and amplified in vitro to obtain enough transduced cells
for in vivo administration.
Animals and transplantation procedures
Timed pregnant White New Zealand rabbits (13–15 days
of gestation) were housed for 1 week before surgery. The
housing was quiet, at constant room temperature and hu-
midity. Laparotomies were performed at 17 days of gestation
(E17) (gestation = 31–32 days), as described previously [16].
The fetus was located and fixed by external palpation of the
semitransparent uterine wall, and intra-amniotic injections
were performed using 26-gauge needles directly in the am-
niotic fluid of the fetal sac in view of the common anatomical
landmarks of the E16–18 embryo [16].
Approximately 20min before the intervention, the EGFP + -
ASCs were trypsinized and resuspended in PBS. Fetuses
received a unique dose of 2· 105 EGFP+ -ASCs in a volume
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of 100 mL/fetus. Control fetuses were injected with an iden-
tical volume of PBS. No more than 50% of the fetuses were
treated per uterine horn (the vaginal-end sacs were always
excluded). Whenever possible, injection of adjacent fetuses
was avoided. Once the injections were completed, the uterus
was returned to the abdominal cavity and the abdomen was
closed in layers. Does were kept under a warming blanket
until awake and active, and received subcutaneous injections
of meloxicam (Metacam; Abbott Laboratories) (0.4mL per
rabbit/24 h) over 48 h as postoperative analgesia.
All procedures were conducted in compliance with ap-
plicable regulations and guidelines, and were reviewed and
approved by the Animal Care Committee.
Tissue collection and processing
On day 31 of gestation (14 days after intervention), preg-
nant rabbits were sacrificed with a euthanizing dose of
pentobarbital (150mg/kg, intravenous). Samples of gonads
and uterus from the does and placenta from the pups were
frozen for DNA extraction. Experimental pups were re-
trieved by visual identification after caesarean section, re-
animated, and weighted. The pups were marked with a
subcutaneous microchip (AVID Microchip ID Systems) for
further identification, kept in an incubator C100 (Air Shields)
at 32C for *1 h, and finally allocated to foster rabbits. At
the end of study (8 or 16 weeks after intervention), the rab-
bits were sacrificed with a euthanizing dose of pentobarbital,
as described above, and tissue samples were harvested (go-
nads, kidney, liver, heart, lung, trachea, and esophagus for
16-week-old pups). A sample fraction was quickly frozen in
liquid nitrogen for DNA extraction, and the remaining frac-
tion was fixed overnight in formalin and embedded in par-
affin for immunohistochemical evaluation.
DNA isolation and polymerase chain
reaction analysis
Genomic DNA was obtained from does and fetal tissues
by standard phenol–chloroform extraction and isopropanol
precipitation. Briefly, samples were washed twice in 1 · SSC
and 10mM EDTA and incubated overnight at 56C in a
sterile lysis buffer [10mM Tris-Cl, pH 10.5; 1mM EDTA;
0.15mM NaCl; 0.5% SDS; 0.3mg/sample proteinase K
(Roche)] before phenol extraction. Vector presence in the
harvested organs was determined by polymerase chain re-
action (PCR) amplification of a provirus-specific fragment
carried out in a 25-mL volume containing 50 ng of genomic
DNA, 100 mM dNTPs, 2.5 mL 10 · Biotaq DNA polymerase
buffer, 1.50mM MgCl2, 0.15 mL Biotaq DNA polymerase
(5U/mL) (Bioline), and 20 pmol of the following primers:
WPT-EGFP-F (5¢-ACC CCG ACC ACA TGA AGC AGC-3¢)
and WPT-EGFP-R (5¢-CGT TGG GGT CTT TGC TCA GGG-
3¢), localized within the EGFP sequence, in a GeneAmp
PCR system 2400 DNA thermocycler (Perkin-Elmer). A
control PCR reaction containing no DNA to monitor for
contamination of PCR reagents and a positive control-
containing vector DNA were included in each PCR analysis.
Amplification conditions involved an initial 10-min dena-
turation step at 94C, followed by 42 cycles (94C, 1min;
60C, 30 s; and 72C, 45 s), and a final 7-min extension at
72C, producing a 417-base-pair DNA fragment. Rabbit
skeletal muscle myosin heavy-chain gene (MHC) primers,
RMMHC-F (5¢-AAAGAAGATGGATGTTGAGGC-3¢), and
RMMHC-R (5¢-TCACCGTCACTTTCCCTGCT-3¢), were used
to amplify a 429-base-pair-specific DNA fragment as de-
scribed previously [17], which served as a control for geno-
mic DNA isolation and loading. All samples were evaluated
through 2% agarose gel electrophoresis.
Immunohistochemistry
Formalin-fixed tissues were dehydrated with an ethanol
gradient, cut, and embedded in paraffin. Sliced 5-mm sections
were mounted on poly-l-lysine-coated glass slides. Before
immunohistochemistry, sections were deparaffinized and
rehydrated. Immunogenic retrieval was performed, incu-
bating the slides in 10mM citrate buffer pH 6.0 for 20min in
a microwave oven. After performing several TBS-T (TBS plus
0.3% Triton X-100) washes, tissue sections were blocked by 2-
h incubation in 10% FBS diluted in a washing buffer [TBS
plus 1% bovine serum albumin (BSA) and 0.2% Tween 20] at
room temperature by gentle agitation. Further, TBS-T-
washed sections were incubated overnight at 4C in a humid
chamber with a biotinylated goat polyclonal anti-GFP
FIG. 1. Long-term assessment of xenogeneic EGFP + -ASC engraftment into young rabbit tissues after fetal transplantation.
(A) Efficient lentiviral vector-mediated transduction of adipose tissue-derived mesenchymal stem cells (ASCs). Lentiviral
vector-transduced ASCs were visualized by enhanced green fluorescent protein (EGFP) fluorescence (magnification: 400 · ;
scale bar = 25 mm). (B) Polymerase chain reaction-mediated detection of integrated, EGFP + -ASC-derived, pWPT-EGFP pro-
virus into genomic DNA isolated from a representative EGFP + -ASC-treated young rabbit at 16 weeks after transplantation.
EGFP-specific primers amplified a 417-bp fragment. Lane 1, 1 kb DNA ladder; lanes 2–9 analysis performed in the indicated
tissues.
3272 MARTI´NEZ-GONZA´LEZ ET AL.
antibody (Abcam) diluted 1/100 in a washing buffer. Next
day, the endogenous peroxidase was blocked with 3% H2O2
for 10min in the dark. Sections were subsequently washed
with PBS and incubated with a biotinylated horseradish
peroxidase–avidin complex (ImmunoPure ABC Peroxidase
Staining Kit; Pierce). Finally, sections were stained with
the peroxidase substrate diaminobenzidine tetrahydrochloride
(DAB; Pierce) and counterstained with hematoxylin. Moreover,
each specimen was routinely stained with hematoxylin/eosin
to evaluate tissue morphology and the presence of inflamma-
tory cell infiltrates.
Enzyme-linked immunosorbent assay
Rabbit sera were obtained at 8 and 16 weeks of age. Blood
was taken from the lateral saphenous vein and left coagu-
lating for*30min. Samples were centrifuged twice at 3000 g
for 10min and kept at - 80C until use.
The generation of a rabbit humoral immune response
against the EGFP reporter protein was assessed by enzyme-
linked immunosorbent assay (ELISA). Maxisorb ELISA 96-
well plates (Nunc) were coated overnight at 4C with 0.1 mg/
well of recombinant EGFP (BioVision) diluted in 50mL of
50mM carbonate buffer (pH 9.6). After several washes with
PBS-T (PBS plus 0.05% Tween 20), plates were blocked with
300 mL of 3% fish gelatin (Sigma-Aldrich) diluted in PBS for
2 h at room temperature. Serum samples diluted 1: 500 with
a dilution buffer (PBS-T + 3% BSA) were incubated in trip-
licate wells for 2 h at room temperature. The plates were then
washed again with PBS-T, and 100mL of secondary antibody
(biotin-conjugated goat anti-rabbit IgG, diluted 1:200,000)
(Sigma-Aldrich) was further incubated for 2 h at 37C. Sub-
sequently, plates were washed with PBS, incubated for
30min with biotinylated horseradish peroxidase–avidin
complex (ImmunoPure ABC Peroxidase Staining Kit; Pierce),
and developed using 1-Step Slow TMB (Pierce) for 30min.
Finally, the reaction was stopped with 2M H2SO4, and the
corresponding absorbances were measured at 450 nm on an
ELISA plate reader. A standard curve was prepared by serial
dilutions of a polyclonal anti-GFP antibody (MBL) in rabbit
serum (prediluted 1: 500 with dilution buffer) to establish the
range of sensitivity.
Mixed lymphocyte culture
After mechanical disaggregation on a culture dish, rabbit
spleens were homogenized by gently flushing with a 21G
needle. The cellular splenocyte suspension was filtered
through a 70-mm nylon filter to remove cellular debris, in-
cubated for 30min with a lysis buffer (0.15M NH4Cl, 10mM
KHCO3, 0.1mM EDTA) at 4C, and centrifuged at 300 g for
5min.
Splenocytes were washed twice with PBS and finally
cultured in a complete DMEM at 37C and 5% CO2 atmo-
sphere. Cell viability was assessed by trypan blue exclusion.
To study the effect of ASCs on lymphocyte reactivity, a 2-
way mixed lymphocyte culture (MLC) was performed.
Lymphoid cells were seeded in triplicate at a concentration of
2 · 105 cells/well in 96-well, U-bottom microtiter cell plates
(Corning), in the presence or absence of 1· 105 ASCs (pas-
sage 2) preplated overnight before the coculture experiment.
After a 5-day incubation period, cell proliferation was de-
termined using the Amersham cell proliferation Biotrack
ELISA system (GE Healthcare Amersham Biosciences).
Results
We intra-amniotically administered a unique dose of
2· 105 EGFP+ -ASCs (100 ml/fetus) into fetal rabbits at day
E17 (control fetuses were injected with an identical volume
of PBS) [14]. At E31 (14 days after intervention), pregnant
rabbits were sacrificed (samples of gonads and uterus from
the does and placenta from the pups were frozen for DNA
extraction), and experimental pups were retrieved by visual
identification after caesarean section, reanimated, and
weighted. Regarding survival, 22 fetuses from 4 pregnant
does were intervened (18 were injected with EGFP + -ASCs,
and 4 were injected with PBS), and 3 abortions were docu-
mented: 2 abortions among the ASC-treated fetuses and 1
abortion among the PBS-treated fetuses. Thus, the overall
survival rate at birth was 86.4%. Furthermore, no anatomical
defects were detected in any of the treated fetuses. They
maintained a correct weight at the termination of pregnancy
according to a normal development pattern. No significant
weight differences were found between EGFP + -ASC- and
PBS-treated young rabbits (mean weight of EGFP + -ASC-
treated fetuses: 56.49– 8.24 g, n = 16, vs. control PBS-treated
fetuses: 57.43– 12.59 g, n= 3) (P= 0.8670, Student’s t-test).
Therefore, neither the intrinsic features of the EGFP + -ASCs
nor the delivery procedure generated toxicity to the in utero-
treated fetuses beyond the standard risk from the surgical
intervention.
After reanimation, 19 treated pups were placed to the care
of a foster mother and 17 survived to adulthood (14 EGFP + -
ASC-treated fetuses and 3 PBS-treated fetuses). Analogously
to that recently reported for in utero EGFP+ -fl-MSC trans-
plantation in the fetal rabbits [14], 2 casualties were docu-
mented among the EGFP+ -ASC-treated pups due to nurturer
rejection. The corresponding necropsies did not reveal any
pathological sign in the deceased animals.
To assess engraftment of transplanted EGFP + -ASCs,
young rabbits were sacrificed at 8 weeks (5 EGFP+ -ASC-
treated and 2 PBS-treated) and 16 weeks (9 EGFP+ -ASC-
treated and 1 PBS-treated) after in utero intervention, and
tissues were collected. Genomic DNA isolated from the
harvested tissues was employed to detect integrated proviral
sequences (Fig. 1B and Table 1). PCR analysis of the EGFP
sequence at 8 weeks after transplantation showed the pres-
ence of donor cells in several tissues from 3 of 5 recipients
(60%), similar to the frequency observed at 16 weeks [6 of 9
recipients (66.7%)]. Each recipient exhibited a different dis-
tribution pattern of donor cells, but their presence in the lung
and trachea was most frequent, accordingly to the intra-
amniotic route of administration. To note, we also detected
the presence of donor cells in some placentas (frequency: 2/
14, 14.3%). In contrast, gonadal tissue was PCR negative.
Moreover, all PBS-treated control animals were completely
negative for the presence of EGFP + -ASC proviral sequences
(data not shown).
We next wanted to confirm fetal homing and engraftment
of EGFP + -ASCs into the different rabbit tissues. Therefore,
we screened transgenic EGFP expression of tissue sections
positive for the presence of pWPT-EGFP provirus sequences
from EGFP + -ASC-treated rabbits, as previously described
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[14]. However, we were not able to substantiate engraftment
of xenogeneic EGFP+ -ASCs into any postnatal in utero-
treated rabbit tissue by immunohistochemistry. We were
also unsuccessful determining EGFP expression at the tran-
scriptional level by real-time quantitative-PCR (RT-qPCR)
(data not shown). Additional examination of the different
tissue sections did not reveal the presence of cellular infil-
trates in any of the analyzed samples, suggesting absence of
immune–inflammatory activity.
Subsequently, we wished to determine the immunoge-
nicity of human ASCs after prenatal transplantation. For this
purpose, we first analyzed whether young rabbits that un-
derwent prenatal transplantation of EGFP+ -ASCs over-
expressing the reporter EGFP protein were able to develop a
humoral immune response against the ASC-derived EGFP
transgene product. A specific ELISA assay detecting the
presence of antibodies against EGFP [14] was performed on
sera harvested from young rabbits after in utero EGFP+ -ASC
delivery (Fig. 2A). There was no evidence of anti-EGFP an-
tibodies in any of the analyzed animals at both 8 and 16
weeks after in utero transplantation.
Finally, through an MLC assay [14], we analyzed whether
young rabbits that underwent prenatal transplantation of
EGFP + -ASCs were able to induce a cellular immune re-
sponse against these xenogeneic cells at 16 weeks after
transplantation. Mononuclear cells isolated from the spleen
of in utero EGFP+ -ASC-transplanted young rabbits were
unable to proliferate when exposed to xenogeneic human
ASCs (Fig. 2B), analogously to that observed from mono-
nuclear cells isolated from an in utero PBS-treated rabbit
spleen. This suggests absence of an immune reaction against
the transplanted human ASCs.
Discussion
Although the most common source of human MSCs is the
adult bone marrow (aBM-MSCs), the invasive methods used
for their obtention and the low number of MSCs present in
the bone marrow (< 0.01% of the bone marrow mononuclear
cell population [18]) stress the need to identify alternative
MSC sources. Over the last decade, ASCs have arisen as a
highly attractive alternative source of MSCs. They are easily
obtained from adipose tissue lipoaspirates using a straight-
forward collagenase-based isolation protocol. Furthermore,
the abundance of ASCs in the original tissue and their
in vitro expansion capacity outperform that from BM-
MSCs [19].
Here, we have presented evidence of the overall safety,
biodistribution, and limited engraftment capacity of geneti-
cally engineered EGFP-expressing adult human ASCs after
xenogeneic fetal transplantation into the pregnant rabbit
model. We have demonstrated that xenogeneic in utero
transplantation of lentiviral vector-transduced human ASCs
is safe both for the recipient dams and for the intervened
offspring. Concerning the overall engraftment frequency of
xenogeneic EGFP + -ASCs into the transplanted fetuses, 60%
and 66.7% of intra-amniotically administered E17 animals
had detectable pWPT-EGFP provirus at 8 and 16 weeks after
EGFP + -ASC delivery, respectively. These frequencies are
analogous to those observed in our previous study using
rabbit fetal liver MSCs transduced with a retrovirus vector
expressing the EGFP reporter (EGFP + -flMSCs) through the
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same route of administration [14]. Moreover, in both studies,
the MSC biodistribution pattern appeared essentially re-
stricted to the primary target organs according to the route of
administration (lung and trachea for intra-amniotic admin-
istration). Both the frequency and depth of fetal breathing
movements where the amniotic fluid is taken in would fa-
cilitate direct contact and further homing and engraftment of
EGFP + -ASCs into respiratory tissues, as we and others have
proven using viral vectors [16,20].
The limited engraftment of EGFP + -ASCs in our immu-
nocompetent fetal rabbits indicates the lack of competitive
advantage of these cells in prenatal recipient niches, similarly
to that reported for in utero hematopoietic cell transplanta-
tion [21]. However, the rather stable levels of microchimer-
ism achieved by the EGFP + -ASCs in the transplanted young
rabbit tissues at both 8 and 16 weeks suggest that the en-
grafted cells were able to overcome the fetal immune barrier
to transplantation. In that sense, it has been recently shown
that in addition of being nonimmunogenic human ASCs
display an even lower susceptibility to natural killer (NK)
cell-mediated lysis than bone marrow-derived MSCs [22].
Indeed, it has been shown that in addition to durable donor-
specific T-cell tolerance [23], the presence of microchimerism
induces NK cell hyporesponsiveness [24], both necessary to
overcome rejection.
Intriguingly, although human ASCs could engraft into the
fetal tissues, being detectable by whole-tissue analysis of the
proviral sequence through PCR, we were unable to detect
EGFP transgene expression in any of the PCR-positive tissue
samples, analyzed both by immunohistochemistry and by
RT-qPCR. Because only a very small fraction of the ASCs
administered in utero could undergo sustained engraftment,
their detection at the cellular level would be complicated.
However, with a comparable low-level engraftment, in our
previously study using rabbit EGFP+ -fl-MSCs, we could
identify a few patchy areas expressing EGFP through im-
munohistochemistry. More likely, the lack of transgene ex-
pression detection might reflect the outcome of epigenetic
events acting over the integrated EGFP-containing provirus.
We have recently shown that the EGFP+ -ASCs gradually
downregulated EGFP transgene expression from integrated
gamma-retroviral vectors. Transgene extinction occurred both
in undifferentiated ASCs and in ASCs differentiated into
2 different cell lineages (adipocytes and osteocytes), and
FIG. 2. Lack of immunogenicity of EGFP + -ASCs in the rabbit host. (A) Specific enzyme-linked immunosorbent assay
(ELISA) to detect the presence of antibodies against EGFP. Serum samples from the in utero EGFP + -ASC-transplanted young
rabbits were collected at sacrifice, and the presence of antibodies against the transgenic EGFP protein was analyzed by
ELISA. (B) Xenogeneic lymphocyte proliferation assessed by mixed lymphocyte culture (MLC). About 2· 105 splenocytes
from the in utero EGFP+ -ASC-transplanted young rabbits were cocultured with 1· 105 xenogeneic ASCs during 5 days in
triplicate wells, and cell proliferation was assessed by ELISA.White column labels refer to the rabbit identification, analyzed 16
weeks after transplantation. Individual values represent the mean– SD from technical replicates (n = 3). Phosphate-buffered
saline (PBS) (black columns) refer to the mean– SD values obtained from control, in utero PBS-treated young rabbits. Statis-
tically significant differences among EGFP + -ASC-transplanted and control PBS-treated rabbits in both the ELISA, and the
MLC assays were estimated using the nonparametric Mann-Whitney U test.
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correlated with increases in H3 histone deacetylation and
CpG dinucleotide methylation within the proviral region
[15]. Furthermore, epigenetic regulation has also been able to
silence lentiviral vector-mediated transgene expression dur-
ing stem cell differentiation in vivo, in transgenic mice
[25,26]. This could limit the efficacy of genetically engineered
ASCs for tissue repair/regeneration applications. In that
case, the optimization of integrative vectors introducing in-
sulators or other cis-regulatory elements allowing the main-
tenance of high-level transgene expression [27] should be
prioritary.
In summary, the results from this report support the po-
tential of intrauterine allogeneic transplantation of ASCs, either
unmodified or genetically engineered using optimized inte-
grative vectors, leading to limited while sustained engraftment
after prenatal application. Therefore, due to their intrinsic im-
munoregulatory features, ASCs might become an alternative to
fetal MSCs, the latter more susceptible to ethical considerations,
attaining microchimerism and leading to prenatal tolerance
induction. This would selectively enhance donor cell competi-
tion, which may become an essential step to boost successful
postnatal ASC transplantation [28,29] for the early treatment/
prevention of many devastating hereditary disorders.
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